» Articles » PMID: 35100926

Discovery of Triterpenoids As Potent Dual Inhibitors of Pancreatic Lipase and Human Carboxylesterase 1

Overview
Specialty Biochemistry
Date 2022 Feb 1
PMID 35100926
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic lipase (PL) is a well-known key target for the prevention and treatment of obesity. Human carboxylesterase 1A (hCES1A) has become an important target for the treatment of hyperlipidaemia. Thus, the discovery of potent dual-target inhibitors based on PL and hCES1A hold great potential for the development of remedies for treating related metabolic diseases. In this study, a series of natural triterpenoids were collected and the inhibitory effects of these triterpenoids on PL and hCES1A were determined using fluorescence-based biochemical assays. It was found that oleanolic acid (OA) and ursolic acid (UA) have the excellent inhibitory effects against PL and hCES1A, and highly selectivity over hCES2A. Subsequently, a number of compounds based on the OA and UA skeletons were synthesised and evaluated. Structure-activity relationship (SAR) analysis of these compounds revealed that the acetyl group at the C-3 site of UA (compound ) was very essential for both PL and hCES1A inhibition, with IC of 0.75 µM and 0.014 µM, respectively. In addition, compound with 2-enol and 3-ketal moiety of OA also has strong inhibitory effects against both PL and hCES1A, with IC of 2.13 µM and 0.055 µM, respectively. Furthermore, compound and exhibited good selectivity over other human serine hydrolases including hCES2A, butyrylcholinesterase (BChE) and dipeptidyl peptidase IV (DPP-IV). Inhibitory kinetics and molecular docking studies demonstrated that both compounds and were effective mixed inhibitors of PL, while competitive inhibitors of hCES1A. Further investigations demonstrated that both compounds and could inhibit adipocyte adipogenesis induced by mouse preadipocytes. Collectively, we found two triterpenoid derivatives with strong inhibitory ability on both PL and hCES1A, which can be served as promising lead compounds for the development of more potent dual-target inhibitors targeting on PL and hCES1A.

Citing Articles

Discovery of natural anthraquinones as potent inhibitors against pancreatic lipase: structure-activity relationships and inhibitory mechanism.

Chen Z, He W, Yang S, Ma H, Zhou J, Li H J Enzyme Inhib Med Chem. 2024; 39(1):2398561.

PMID: 39223707 PMC: 11373360. DOI: 10.1080/14756366.2024.2398561.


Enhanced Enzymatic Performance of Immobilized Lipase on ZIF-8@ZIF-67 and Its Application to the Synthesis of Neryl Acetate with Transesterification Reaction.

Wang Q, Xiong J, Xu H, Sun W, Pan X, Cui S Molecules. 2024; 29(12).

PMID: 38930986 PMC: 11207022. DOI: 10.3390/molecules29122922.

References
1.
Motamed N, Rabiee B, Roozafzai F, Zamani F, Faraji A, Maadi M . Metabolic syndrome and cardiovascular risk assessment tools' estimations of 10-year cardiovascular risk: a population-based study. Acta Cardiol. 2017; 73(5):439-446. DOI: 10.1080/00015385.2017.1410335. View

2.
Zhang J, Yang Y, Qian X, Song P, Zhao Y, Guan X . Design, Synthesis, and Structure-Activity Relationship Study of Pyrazolones as Potent Inhibitors of Pancreatic Lipase. ChemMedChem. 2021; 16(10):1600-1604. DOI: 10.1002/cmdc.202000850. View

3.
Lian J, Nelson R, Lehner R . Carboxylesterases in lipid metabolism: from mouse to human. Protein Cell. 2017; 9(2):178-195. PMC: 5818367. DOI: 10.1007/s13238-017-0437-z. View

4.
Lian J, Bahitham W, Panigrahi R, Nelson R, Li L, Watts R . Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1863(7):688-699. DOI: 10.1016/j.bbalip.2018.04.002. View

5.
Shi D, Yang J, Yang D, LeCluyse E, Black C, You L . Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2006; 319(3):1477-84. DOI: 10.1124/jpet.106.111807. View